Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation Alfred D. Nelson et al. Summary Background Although bloating is a highly prevalent and troublesome symptom in irritable bowel syndrome with constipation (IBS-C), treatment is empirical with no specific guidelines for its management. Aim To conduct a…
Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA) A Randomized Clinical Trial Jeffry Florian et al. IMPORTANCE In 2019, the US Food and Drug Administration (FDA) received a citizen petition indicating that ranitidine contained the probable human carcinogen N-nitrosodimethylamine (NDMA). In addition, the petitioner proposed that ranitidine could convert to NDMA in humans;…
The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis Jean-Frédéric LeBlanc et al. Abstract The gut microbiome has been implicated in a range of diseases and there is a rapidly growing understanding of this ecosystem’s importance in inflammatory bowel disease. We are yet to identify a single microbe that causes either ulcerative colitis (UC)…
The Evidence Behind Robot-Assisted Abdominopelvic Surgery. A Systematic Review Naila H. Dhanani, eta al. Background: Use of robot-assisted surgery has increased dramatically since its advent in the 1980s, and nearly all surgical subspecialties have adopted it. However, whether it has advantages compared with laparoscopy or open surgery is unknown. Purpose: To assess the quality of…
Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment Ramzi Hassouneh and Jasmohan S. Bajaj Simple Summary: Treatment of advanced liver disease and its complications continue to be a challenge due to the complexity of this illness. In recent years, the gut microbiome has been recognized to play a…
Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra (tocilizumab) for the treatment of hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation,…